➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Dow
Merck
Boehringer Ingelheim
Express Scripts

Last Updated: August 7, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR METHYLPHENIDATE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Methylphenidate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000268 Cocaine Abuse and Attention Deficit Disorder - 3 Completed New York State Psychiatric Institute N/A 1995-05-01 The purpose of this study is to evaluate cocaine abuse and Attention Deficit Disorder
NCT00000268 Cocaine Abuse and Attention Deficit Disorder - 3 Completed National Institute on Drug Abuse (NIDA) N/A 1995-05-01 The purpose of this study is to evaluate cocaine abuse and Attention Deficit Disorder
NCT00003266 Methylphenidate in Treating Patients With Melanoma Completed National Cancer Institute (NCI) Phase 3 1999-06-01 RATIONALE: Methylphenidate may relieve some of the side effects of chemotherapy in patients with melanoma. It is not known whether receiving methylphenidate is more effective than receiving no further therapy in treating patients with melanoma. PURPOSE: Randomized phase III trial to determine if methylphenidate is more effective than no further therapy for the relief of fatigue and drowsiness in treating patients with melanoma who have received high-dose interferon alfa for 8-24 weeks.
NCT00003266 Methylphenidate in Treating Patients With Melanoma Completed Eastern Cooperative Oncology Group Phase 3 1999-06-01 RATIONALE: Methylphenidate may relieve some of the side effects of chemotherapy in patients with melanoma. It is not known whether receiving methylphenidate is more effective than receiving no further therapy in treating patients with melanoma. PURPOSE: Randomized phase III trial to determine if methylphenidate is more effective than no further therapy for the relief of fatigue and drowsiness in treating patients with melanoma who have received high-dose interferon alfa for 8-24 weeks.
NCT00012584 Treatment of Youth With ADHD and Anxiety Completed National Institute of Mental Health (NIMH) N/A 2000-11-01 The purpose of this NIMH-sponsored pilot study is to collect information on the efficacy and safety of drug treatments for children and adolescents who suffer from both ADHD and anxiety disorders. Specifically, the study will examine the benefits of the stimulant medication both alone and in combination with fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) that has antianxiety effects. Young people aged 6 to 17 diagnosed with these co-occurring disorders may be eligible to participate.
NCT00015054 Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3 Completed Cincinnati MDRU Phase 2 1998-09-01 The purpose of this study is to demonstrate the feasibility of methylphenidate (MPD) as effective and safe in the outpatient treatment of cocaine-dependent patients with a comorbid DSM-IV diagnosis of Attention Deficit Hyperactivity Disorder (ADHD), to demonstrate the ability of each site to participate in a subsequent anticipated controlled trial of MPD (recruitment and execution), and to gather preliminary data on the ability of sweat patches to detect episodes of cocaine use.
NCT00015054 Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3 Completed National Institute on Drug Abuse (NIDA) Phase 2 1998-09-01 The purpose of this study is to demonstrate the feasibility of methylphenidate (MPD) as effective and safe in the outpatient treatment of cocaine-dependent patients with a comorbid DSM-IV diagnosis of Attention Deficit Hyperactivity Disorder (ADHD), to demonstrate the ability of each site to participate in a subsequent anticipated controlled trial of MPD (recruitment and execution), and to gather preliminary data on the ability of sweat patches to detect episodes of cocaine use.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Methylphenidate

Condition Name

Condition Name for Methylphenidate
Intervention Trials
Attention Deficit Hyperactivity Disorder 95
Attention Deficit Disorder With Hyperactivity 44
ADHD 41
Healthy 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Methylphenidate
Intervention Trials
Attention Deficit Disorder with Hyperactivity 206
Hyperkinesis 143
Disease 84
Fatigue 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Methylphenidate

Trials by Country

Trials by Country for Methylphenidate
Location Trials
United States 603
Canada 36
Israel 24
Germany 21
France 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Methylphenidate
Location Trials
California 46
Massachusetts 40
New York 39
Texas 38
Ohio 38
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Methylphenidate

Clinical Trial Phase

Clinical Trial Phase for Methylphenidate
Clinical Trial Phase Trials
Phase 4 130
Phase 3 81
Phase 2/Phase 3 12
[disabled in preview] 88
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Methylphenidate
Clinical Trial Phase Trials
Completed 209
Recruiting 65
Not yet recruiting 35
[disabled in preview] 68
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Methylphenidate

Sponsor Name

Sponsor Name for Methylphenidate
Sponsor Trials
Massachusetts General Hospital 28
National Institute of Mental Health (NIMH) 27
National Institute on Drug Abuse (NIDA) 19
[disabled in preview] 47
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Methylphenidate
Sponsor Trials
Other 371
Industry 134
NIH 72
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Boehringer Ingelheim
Harvard Business School
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.